All News

A Kaiser Family Foundation web briefing navigated the HIV/AIDS funding landscape, taking a look at trends over time, the latest data, and what we might expect in the future.

Health officials are warning of an unusually harsh flu season; Ascension and Providence St. Joseph Health are in talks about a possible merger; and heavy traffic is expected as the final week of ACA sign-ups begins.

The Institute for Clinical and Economic Review (ICER) is seeking public comment on its review of 3 calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine, as well as an update to its 2016 report on treatments for plaque psoriasis.

This article focuses on the financial results that may accrue to a participating hospital throughout the remainder of the Comprehensive Care for Joint Replacement program as a result of the migration from historical baseline to regional target rates, and rebasing of the historical baseline.

The American Diabetes Association update has recommendations that affect liraglutide, canagliflozin, and empagliflozin.

Infantile spasms are hard to diagnose, which can lead to treatment delays, according to the study authors.

A University of California San Diego School of Medicine and Moores Cancer Center research team studying new drugs that could break resistance to cancer immunotherapy has received a 3-year, $600,000 translational grant from the V Foundation for Cancer Research.

AJMC provides a look at some of the updates coming out of the FDA this week, from new guidance on digital health oversight to multiple new drug approvals.

CMS' update to the Medicare Advantave Value-Based Insurance Design Model, demonstrate CMS’ continued commitment to expanding the demonstration and allowing participating plans more flexibility for customized benefit designs.

Los Angeles County found that investing in supportive housing and combating homelessness among people with complex medical and behavioral health issues ultimately saved the county money.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

How counties, cities, and schools are saving money by importing drugs for employees; insurers are finally turning a profit on their Obamacare plans; new report projects the number of Americans with Alzheimer's disease will more than double by 2060.

This week, the top managed care stories included CVS' proposal to purchase Aetna, which could reshape healthcare; a new study that looks at who is dying in hospitals from opioid use; and CMS reported that healthcare spending grew more slowly in 2016.

After reporting positive results of a lead investigational digital medicine, a company is planning to file for FDA approval of a video game to treat attention-deficit/hyperactivity disorder.

Last week, CMS announced its “Meaningful Measures” initiative, seeking to streamline quality and cost measures. The sheer number of quality measures have soared over the last decade, and CMS said that part of its reasoning is to reduce the burden of quality reporting on healthcare providers so they can spend more time with patients. The burden of reporting such measures have long been noted to increase the stress on healthcare providers­.

Novartis announced that Phase III MONALEESA-7 trial results showed that the combination of ribociclib with an endocrine therapy (tamoxifen or an aromatase inhibitor) and goserelin yielded significant progression-free survival when compared with endocrine therapy and goserelin alone.

According to a new study published in JAMA Dermatology, older patients had better clinical outcomes than their younger comparator cohort following treatment with newer immunotherapy agents for their advanced melanoma.

The use of healthcare services, with the exception of physiotherapy and psychotherapy, in patients with chronic back pain was lower 6 months after rehabilitation in Germany than before rehabilitation, according to a study published in BMC Health Services Research.

A recent study in The American Journal of Clinical Dermatology led by Igor Snast, MD, sought to evaluate the efficacy and safety of biologic agents in the treatment of atopic dermatitis (AD). The results of the study showed that in particular, dupilumab stood out.

House Speaker Paul Ryan, R-Wisconsin, is eyeing spending cuts to Medicare and Medicaid; Louisiana's Medicaid program reported lower-than-expected spending and a potential surplus; ACA enrollment continues to climb, but expected to fall short of 2017 due to shorter enrollment period.

Landmark study shows clot-busting drugs not recommended for most patients with secondary blood clots in the legs.

Clinical trial transparency is high among large pharmaceutical companies, according to a new study, although there remains room for improvement in companies’ reporting of their data.

The rate of healthcare spending in the United States slowed down last year to levels previously seen between 2008-2015, driven by much slower growth in spending for retail prescription drugs, as well as hospital care and physician and clinical services. Private payers, Medicaid, and Medicare­ also saw lower rates of spending growth.

A study published in the Journal of Managed Care & Specialty Pharmacy found that filgrastim and filgrastim-sndz were noninferior for the prevention of febrile neutropenia events that would require hospitalization. However, inferiority could not be established for serious adverse events.

Humana may also make an acquisition deal and UnitedHealth buys a unit of DaVita; a look at the FDA's expedited review programs; how a billing code discrepancy may have cost taxpayers up to $102 million in Medicare payments to hospitals.

WIth different societies and organizations releasing contrary guidelines around breast cancer screening, experience with past patients or friends and family members could influence physicians' decisions around when to start screening mammography.

A Samfund grant recipient narrates her experience of being diagnosed young with cancer and how the support from The Samfund "made everyday school and life manageable."

For high-risk patients with hematological malignancies and febrile neutropenia, empirical antimicrobial therapy can be discontinued after 72 hours of apryexia and clinical recovery regardless of their neutrophil count, according to a study in The Lancet Hematology. The traditional approach of continuing the initial regimen of EAT in neutropenic patients with unexplained fever until neutrophil recovery could result in unnecessarily prolonged EAT.

A new study published Monday by scientists at the University of Massachusetts Medical School (UMMS) in Boston reports findings on a gene that is responsible for creating a protein that may help melanoma to grow and metastasize.

A systematic review of the FDA’s Adverse Event Reporting System (FAERS) found elevated reporting for both tofacitinib (Xeljanz) and ruxolitinib (Jakafi) for thromboembolic adverse events (AEs), suggesting the possibility of a class-wide issue with Janus kinase (JAK) inhibitors.